Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$93.00 USD
+2.27 (2.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $93.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -506.98 | -557.52 | -644.09 | 313.88 | -347.69 |
Depreciation/Amortization & Depletion | -5.80 | 10.75 | 7.84 | 7.03 | 0.31 |
Net Change from Assets/Liabilities | -41.13 | -53.77 | -23.68 | -15.62 | 9.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 117.07 | 98.26 | 361.27 | 81.75 | 59.64 |
Net Cash From Operating Activities | -436.85 | -502.28 | -298.65 | 387.04 | -278.02 |
Property & Equipment | -16.06 | -8.92 | -3.09 | -3.16 | -14.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 290.10 | -140.33 | 35.38 | -431.09 | -2.45 |
Other Investing Activities | 0.00 | -0.29 | -258.15 | 0.00 | 0.00 |
Net Cash from Investing Activities | 274.04 | -149.54 | -225.86 | -434.25 | -16.47 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 21.34 | 8.20 | 50.72 | 617.76 | 341.04 |
Issuance (Repayment) of Debt | 97.93 | 553.61 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.04 | 0.00 | 0.00 | 0.00 | -0.40 |
Net Cash from Financing Activities | 119.23 | 561.81 | 50.72 | 617.76 | 340.64 |
Effect of Exchange Rate Changes | 0.20 | -0.21 | -0.89 | -0.35 | 0.02 |
Net Change In Cash & Equivalents | -43.38 | -90.22 | -474.69 | 570.20 | 46.18 |
Cash at Beginning of Period | 124.90 | 215.12 | 689.80 | 119.60 | 73.43 |
Cash at End of Period | 81.52 | 124.90 | 215.12 | 689.80 | 119.60 |
Diluted Net EPS | -8.37 | -9.35 | -11.01 | 5.59 | -7.27 |
Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -506.98 | -396.07 | -262.35 | -129.56 |
Depreciation/Amortization & Depletion | NA | -5.80 | -1.39 | 7.26 | 3.68 |
Net Change from Assets/Liabilities | NA | -41.13 | -51.53 | -54.50 | -26.42 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 117.07 | 91.07 | 56.16 | 29.34 |
Net Cash From Operating Activities | NA | -436.85 | -357.92 | -253.44 | -122.96 |
Property & Equipment | NA | -16.06 | -11.39 | -5.14 | -2.58 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 290.10 | 206.66 | 210.00 | 175.38 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 274.04 | 195.27 | 204.86 | 172.79 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 21.34 | 5.73 | 5.30 | 0.00 |
Issuance (Repayment) of Debt | NA | 97.93 | 97.97 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.04 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 119.23 | 103.70 | 5.30 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.20 | -0.29 | 0.26 | 0.20 |
Net Change In Cash & Equivalents | NA | -43.38 | -59.24 | -43.03 | 50.03 |
Cash at Beginning of Period | NA | 124.90 | 124.90 | 124.90 | 124.90 |
Cash at End of Period | NA | 81.52 | 65.67 | 81.88 | 174.93 |
Diluted Net EPS | NA | -1.83 | -2.20 | -2.19 | -2.15 |